Inflammatory cascade mediators

Inflammatory cascade mediators are a heterogeneous group of endogenous signaling molecules that coordinate the complex biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants (StatPearls, 2023). This broad category encompasses various classes of molecules, including cytokines (e.g., TNF, IL-1, IL-6), chemokines, lipid-derived eicosanoids (e.g., prostaglandins, leukotrienes), and plasma-derived proteins like those in the complement and kinin systems (Nature Reviews Immunology, 2018). These mediators function by binding to specific receptors on target cells, triggering intracellular signaling pathways that lead to physiological changes such as vasodilation, increased vascular permeability, and leukocyte recruitment (PubMed, PMC7151630). While acute inflammation is a protective mechanism essential for host defense and tissue repair, the chronic or excessive production of these mediators is central to the pathogenesis of many diseases, including rheumatoid arthritis, asthma, atherosclerosis, and sepsis (NIH, 2022). Consequently, many of these individual mediators or their receptors serve as critical therapeutic targets for anti-inflammatory and immunomodulatory drugs (PubChem). Because this term refers to a functional group of diverse molecules rather than a single protein or receptor, it is classified as a category of targets rather than a specific therapeutic target.

Other names

Inflammatory mediatorsPro-inflammatory mediatorsChemical mediators of inflammationInflammatory signaling moleculesInflammatory cytokines and eicosanoids

Drugs targeting these mediators typically act by inhibiting the enzymes responsible for their synthesis (e.g., cyclooxygenase inhibitors), neutralizing the mediators themselves using monoclonal antibodies (e.g., anti-TNF or anti-IL-6 agents), or blocking their respective receptors to prevent downstream signaling (StatPearls, 2023; PubMed, PMC7151630).